Poland Lung Cancer Therapeutics Market Report 2022 to 2030

Poland Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Poland Lung Cancer Therapeutics Market will reach a value of $333 Mn from $173 Mn in 2022, growing at a CAGR of 8.6% during 2022-2030. The Lung Cancer Therapeutics Market in Poland is dominated by a few domestic pharmaceutical companies such as Adamed Group, Polpharma Group, and Gedeon Richter Polska. The Lung Cancer Therapeutics Market in Poland is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Poland lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10PLPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Poland AUTHOR: Dr. Vishwa Modhia

Buy Now

Poland Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Poland Lung Cancer Therapeutics market will reach a value of $333 Mn from $173 Mn in 2022, growing at a CAGR of 8.6% during 2022-2030.

Poland is a high-income, developed country in Central Europe bordered by Belarus, the Czech Republic, Germany, Lithuania, Russia, Slovakia, and Ukraine. Over 22,000 Poles were diagnosed with lung cancer in 2017. According to the European Standard Population, the incidence rates for males and women are 93 and 38 per 100,000 in 2013, respectively. Lung cancer is the most common type of cancer overall, accounting for around 18% of cancer cases in men and 10% in women. Lung cancer mortality among Polish women has been steadily increasing, corresponding with the continued increase in smoking prevalence.

The Polish Society of Clinical Oncology develops and publishes recommendations for the systemic treatment of lung cancer every 2 to 3 years. Two national cooperative groups do academic lung cancer research: the Polish Lung Cancer Group and the Central and East European Oncology Group. According to the latest WHO data published in 2020 Lung Cancers Deaths in Poland reached 25,781 or 7.23% of total deaths. The age-adjusted Death Rate is 34.89 per 100,000 population ranks Poland 6^th in the world. Poland's government spends 6.5% of its GDP on healthcare.

Poland Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

18 of the 27 authorised Polish thoracic surgical units perform more than 100 anatomical resections every year. In 2017, 4031 lung cancer anatomical resections were conducted in Poland. Radiotherapy equipment has been effectively supplemented and modernised during the last two decades to satisfy European Union regulations. The number of high-energy external beam units increased from 70 to more than 170 between 2005 and 2018, nearly closing the historical infrastructure gap. In cancer centres, pulmonary hospitals, and medical oncology clinics, standard cytotoxic therapy is frequently accessible. These aspects could boost Poland's Lung Cancer Therapeutics market.

Market Restraints

Although the outcomes of lung cancer treatment appear to be marginally better than in other countries in Central and Eastern Europe, there is still room for improvement. 4 With the enormous burden of lung cancer in Poland, several initiatives from both governmental and professional medical organisations, as well as patient advocacy groups, are focusing on the most pressing challenges. In general, Poland does not spend on R&D and imports a large number of its exports. These factors may deter new entrants into the Poland Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Adamed Group: Adamed Group is a Polish pharmaceutical and biotechnology company that specializes in the development and production of innovative medicines. The company offers a range of lung cancer treatments including chemotherapy drugs and targeted therapies
Polpharma Group: Polpharma Group is a Polish pharmaceutical company that specializes in the development and production of generic and branded medicines
KRKA Polska: KRKA Polska is a Polish subsidiary of KRKA, a Slovenian pharmaceutical company. The company offers a range of lung cancer treatments including chemotherapy drugs and targeted therapies
Gedeon Richter Polska: Gedeon Richter Polska is a Polish subsidiary of Gedeon Richter, a Hungarian pharmaceutical company.
Polfa Tarchomin: Polfa Tarchomin is a Polish pharmaceutical company that specializes in the production of generic medicines

Recent Notable Updates

January 2022: Poland's top drugmaker Polpharma is working on a $4 Bn buyout of Czech rival Zentiva and is looking for investors to join its bid in exchange for a minority stake in the Advent International firm. Polpharma's discussions with potential partners are still in the early stages, and the Polish company has yet to decide how it will organise a joint bidding vehicle.

Healthcare Policies and Reimbursement Scenarios

In Poland, the regulatory authority responsible for the approval and regulation of therapeutic products, including lung cancer therapeutics, is the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Poland has a universal nationwide public health insurance system that provides fully reimbursable care to almost all citizens, including modern diagnostic and therapeutic procedures such as positron emission tomography-computed tomography (CT) imaging, video-assisted thoracic surgery, stereotactic body radiotherapy, targeted agents, and immunotherapy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.